HCV-3: sofosbuvir plus daclatasvir is the best option

Takeaway

• A combination of sofosbuvir (SOF) plus daclatasvir (DCV) is the best option for treating hepatitis C virus (HCV)-3; add-on ribavirin (RBV) is not needed to achieve high clearance rates.

Study design

• Meta-analysis of 12 randomized clinical trials and prospective National Cohort Studies involving patients with HCV-3 treated with combinations of SOF, DCV, ledipasvir (LDV), peginterferon (PegIFN), and RBV.
• The primary outcome was sustained virologic response (SVR).

Key results

• Data from 4 studies (n=807) showed that adding PegIFN to SOF and RBV significantly improved SVR rates (92.5% vs 75.2%; OR, 3.51; 95% CI, 2.08-5.92).
• Data from 4 studies (n=850) demonstrated that a 24-wk course of SOF + RBV was better than a 12- to 16-wk course for achieving SVR (85.5% vs 70%; OR, 3.51; 95% CI, 1.59-7.70).
• Data from 4 studies (n=502) showed that the addition of RBV to SOF + DCV was not required to achieve hi...